Why NAM metadata should be mandatory before qualification

Qualification is not just assay performance

A New Approach Methodology can be biologically promising and still be weak regulatory evidence. Qualification requires a clear context of use: what decision the method supports, in which biological system, for which endpoint, and under what limitations. FDA's Drug Development Tool qualification process is built around collecting evidence for a prospectively specified context of use, not around a general claim that a tool is useful.

That framing makes metadata mandatory. Context of use, test system identity, exposure conditions, endpoint definitions, controls, acceptance criteria, reproducibility evidence, and uncertainty are not annotations added after the science is complete. They are the record that makes the science assessable.

Regulators already require standardised data logic

FDA's CDER Data Standards Program states the operational reason plainly: standards make submissions predictable, consistent, and usable by information technology systems and scientific tools. NAMs add more heterogeneity than conventional nonclinical studies, so the need is stronger, not weaker. Organoids, MPS platforms, QSAR models, PBPK simulations, and AI-derived endpoints all need a common metadata discipline if they are expected to contribute to regulatory decisions.

OECD's QSAR validation principles are a useful precedent for computational NAMs. A model needs a defined endpoint, unambiguous algorithm, applicability domain, performance measures, and mechanistic interpretation when possible. These are scientific requirements, but they are also structured metadata requirements.

Minimum-information standards show the direction

The minimum-information movement exists because free-text methods sections do not reliably support reuse. MIACA proposed a minimum information guideline and a cellular assay object model for cellular assay exchange. MIRCA provides reporting recommendations for the comet assay. These efforts are not paperwork exercises; they identify the minimum experimental context needed to understand how data were generated.

NAM development should adopt the same discipline earlier. A platform should not be considered reusable until its required metadata is known, versioned, validated, and captured during execution. Without that, each successful experiment remains a local result rather than a reusable evidence object.

The commercial risk is false platform ROI

A non-standardised NAM platform can still be useful for a single programme. The problem appears when the platform is justified as reusable infrastructure. If results cannot be merged with historical animal data, clinical biomarkers, compound identifiers, exposure records, or external benchmarks, the organisation has bought an assay service rather than a durable data asset.

Mandatory metadata changes the procurement and qualification question. The right question is not only whether the platform predicts a toxicity or disease-relevant phenotype. It is whether it produces outputs that survive review, warehouse integration, model training, and evidence synthesis across programmes.